Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Covalent tyrosine kinase inhibitors bind and inactivate EGFR kinase domain mutant dimers resistant to non-covalent tyrosine kinase inhibitors

Class:Id	Reaction:1220611
_displayName	Covalent tyrosine kinase inhibitors bind and inactivate EGFR kinase domain mutant dimers resistant to non-covalent tyrosine kinase inhibitors
_doRelease	TRUE
_timestamp	2011-11-23 11:09:26
authored	[InstanceEdit:1972359] Orlic-Milacic, M, 2011-11-04
compartment	[Compartment:876] plasma membrane [Compartment:70101] cytosol [Compartment:984] extracellular region
created	[InstanceEdit:1220609] Orlic-Milacic, Marija, 2011-02-22
disease	[Disease:1500689] cancer
edited	[InstanceEdit:1972360] D'Eustachio, P, 2011-11-07 [InstanceEdit:1972361] Matthews, L, 2011-11-07 [InstanceEdit:1990858] Jassal, B, 2011-11-07 [InstanceEdit:1990853] Wu, G, 2011-11-07
input	[DefinedSet:1220585] Resistant ligand-responsive EGFR mutants [plasma membrane] [Homo sapiens] [DefinedSet:1216522] Covalent EGFR tyrosine kinase inhibitors [cytosol] [DefinedSet:1216522] Covalent EGFR tyrosine kinase inhibitors [cytosol]
isChimeric	FALSE
literatureReference	[LiteratureReference:1225967] Novel mutant-selective EGFR kinase inhibitors against EGFR T790M [LiteratureReference:2008190] Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
modified	[InstanceEdit:1225977] Orlic-Milacic, Marija, 2011-03-03 [InstanceEdit:1226005] Orlic-Milacic, Marija, 2011-03-04 [InstanceEdit:1235102] Orlic-Milacic, Marija, 2011-03-23 [InstanceEdit:1236390] Orlic-Milacic, Marija, 2011-03-25 [InstanceEdit:1246130] Orlic-Milacic, Marija, 2011-04-01 [InstanceEdit:1247612] Orlic-Milacic, Marija, 2011-04-04 [InstanceEdit:1247850] Orlic-Milacic, Marija, 2011-04-07 [InstanceEdit:1247851] Orlic-Milacic, Marija, 2011-04-07 [InstanceEdit:1643692] Orlic-Milacic, Marija, 2011-10-11 [InstanceEdit:1660495] Orlic-Milacic, Marija, 2011-10-13 [InstanceEdit:1979631] Orlic-Milacic, Marija, 2011-11-08 [InstanceEdit:1990842] Orlic-Milacic, Marija, 2011-11-14 [InstanceEdit:1990860] Orlic-Milacic, Marija, 2011-11-14 [InstanceEdit:2008188] Orlic-Milacic, Marija, 2011-11-22 [InstanceEdit:2023591] Matthews, L, 2011-12-09 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	Covalent tyrosine kinase inhibitors bind and inactivate EGFR kinase domain mutant dimers resistant to non-covalent tyrosine kinase inhibitors
output	[Complex:1220579] Resistant ligand-responsive EGFR mutants:Covalent EGFR TKIs [plasma membrane] [Homo sapiens]
precedingEvent	[Reaction:1220610] Non-covalent tyrosine kinase inhibitors bind and inactivate sensitive ligand-responsive EGFR cancer mutants [Homo sapiens] [Reaction:1220613] EGF-induced dimerization of ligand-responsive EGFR mutants [Homo sapiens] [Reaction:1220614] Spontaneous dimerization of ligand-responsive EGFR mutants [Homo sapiens]
releaseDate	2011-12-06
reviewed	[InstanceEdit:1990843] Greulich, H, 2011-11-15 [InstanceEdit:1990844] Savas, S, 2011-11-15
reviewStatus	[ReviewStatus:9821382] five stars
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:2016310] R-HSA-1220611.2
summation	[Summation:1225971] Covalent (irreversible) tyrosine kinase inhibitors (TKIs), p...
(hasEvent)	[Pathway:1169434] Signaling by constitutively active EGFR kinase domain mutants [Homo sapiens] [Pathway:1236382] Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by Covalent tyrosine kinase inhibitors bind and inactivate EGFR kinase domain mutant dimers resistant to non-covalent tyrosine kinase inhibitors (1220611)